|
Press Releases |
|
|
|
Monday, September 14, 2015 |
|
Eisai to Present Latest Clinical Data on Lenvima (Lenvatinib) and Halaven (Eribulin) at European Cancer Congress |
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Lenvima and Halaven will be presented during the European Cancer Congress (ECC) 2015, taking place in Vienna, Austria, from September 25 to 29. more info >> |
|
Thursday, September 10, 2015 |
|
Drugs for Neglected Diseases initiative and Eisai to Test Drug Candidate for Eumycetoma Patients suffering from virtually no R&D for this neglected disease |
The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases. more info >> |
|
Friday, July 31, 2015 |
|
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer |
Eisai Co., Ltd. and Halozyme Therapeutics, Inc. announced today that they have signed a clinical collaboration agreement to evaluate Eisai's anticancer agent eribulin mesylate in combination with Halozyme's investigational new drug PEGPH20 in first line HER2-negative advanced breast cancer. more info >> |
|
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)" |
The Board of Directors of Eisai Co., Ltd. passed a resolution for the continuation of the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders", which was proposed by the Independent Committee of Outside Directors at its meeting held today. more info >> |
|
Wednesday, July 29, 2015 |
|
Eisai's In-House Developed Novel Anticancer Agent Lenvima Receives Breakthrough Therapy Designation From U.S. Fda for Renal Cell Carcinoma |
Eisai Co., Ltd. announced today its U.S. subsidiary Eisai Inc. has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent Lenvima for the potential indication of advanced and/or metastatic renal cell carcinoma. more info >> |
|
Friday, June 26, 2015 |
|
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for Pediatric Patients in Japan |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it will launch Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate), on June 29 in Japan. more info >> |
|
Monday, June 22, 2015 |
|
U.S. FDA Approves Eisai's Antiepileptic Agent Fycompa as Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. more info >> |
|
Monday, June 1, 2015 |
|
Eisai Receives European Commission Approval of Anticancer Agent Lenvima for Treatment of Advanced Thyroid Cancer Refractory to Radioactive Iodine |
Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has received approval from the European Commission (EC) for anticancer agent Lenvima (lenvatinib mesylate) in the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hurthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). more info >> |
|
Friday, May 29, 2015 |
|
AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA, a Fully Human Anti-TNF-alpha Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis |
AbbVie GK and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of HUMIRA Pre-filled Syringe 40 mg / 0.8 mL, a fully human anti-TNF-alpha monoclonal antibody formulation, has been lifted for use in patients with ankylosing spondylitis. more info >> |
|
Wednesday, May 27, 2015 |
|
Eisai Submits New Drug Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis in Japan |
Eisai Co., Ltd. announced today that it has submitted a new drug application for mecobalamin (development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
MHI Thermal Systems Receives Order for Large-scale Centrifugal Chillers from Empower for its District Cooling Plants in Dubai, UAE
Oct 18, 2024 11:20 JST
|
|
|
Fujitsu and Teikyo University begin joint research on UX platform for promotion of lifestyle improvement using XR, spatial computing, and generative AI
Oct 18, 2024 10:38 JST
|
|
|
DPC Dash - Domino's Pizza China Drives Sales and Profit Growth and Optimizes Shareholder Structure
Oct 18, 2024 07:00 HKT/SGT
|
|
|
TANAKA to Provide Medals Representing the Event Concept with a Design of Gently Curved Circular Expansion for the Tokyo Legacy Half Marathon 2024
Oct 18, 2024 3:00 JST
|
|
|
Participation in the Multilateral System Remains High as Performance Drops, New Index Finds
Oct 18, 2024 01:00 HKT/SGT
|
|
|
Join the Top 1% of Web3: VAP Group Presents Global Blockchain Show in Dubai
Oct 17, 2024 23:00 HKT/SGT
|
|
|
Learn & Get Inspired at the Global STEM Confex
Oct 17, 2024 22:26 HKT/SGT
|
|
|
Moolec Has Received USDA Approval for the First Genetically Modified Pea in History
Oct 17, 2024 22:00 HKT/SGT
|
|
|
Embracing the Future of Manufacturing with the 26th Edition of the South Africa Manufacturing Show
Oct 17, 2024 22:00 HKT/SGT
|
|
|
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
Oct 17, 2024 21:00 HKT/SGT
|
|
|
GTJAI Signed the Good Employer Charter Again
Oct 17, 2024 19:43 HKT/SGT
|
|
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 20:01 JST
|
|
|
Eco Expo Asia opens at AsiaWorld-Expo in late October
Oct 17, 2024 19:01 HKT/SGT
|
|
|
Graphene Manufacturing Group (GMG) Provides Commercialisation Update on Energy Savings Coating THERMAL-XR(R)
Oct 17, 2024 17:00 HKT/SGT
|
|
|
Kincora Announces Strategic Investment & Expanded Partnership with Fleet Space
Oct 17, 2024 16:40 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|